Health Plans Defend Renewed Biogen MS Drug Scheme Suit

By Editorial Team

Health plans alleging that Biogen Inc. engaged in anticompetitive practices regarding its multiple sclerosis drug Tecfidera are pushing for their latest complaint to proceed to discovery in an Illinois federal court. The health plans argue that the new complaint addresses previous pleading deficiencies and provides a clearer outline of the drugmaker’s alleged anticompetitive behavior.

The health plans are represented by law firms including Cohen Milstein, Glancy Prongay, Hilliard Shadowen, Jones Day, and Sperling Kenny. Biogen Inc. is the defendant in this case, which is being heard at the U.S. District Court for the Northern District of Illinois.

The case details, including the case title, number, court, nature of suit, and judge, are available only to subscribers. The health plans’ argument is based on the claim that Biogen Inc. unlawfully restricted competition for Tecfidera, a medication used in the treatment of multiple sclerosis.

The ongoing legal battle between the health plans and Biogen Inc. showcases the complex nature of antitrust and competition law within the pharmaceutical industry. The outcome of this case could have significant implications for future drug pricing and competition in the healthcare sector.